Published in Genes Dev on April 15, 2000
The first 30 years of p53: growing ever more complex. Nat Rev Cancer (2009) 8.00
Gene expression patterns in human liver cancers. Mol Biol Cell (2002) 6.93
E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. Genes Dev (2001) 6.13
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A (2006) 4.68
Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol (2006) 4.54
Understanding protein non-folding. Biochim Biophys Acta (2010) 4.33
p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell (2009) 4.30
Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev (2006) 4.06
Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer (2009) 4.06
Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A (2000) 3.74
The expanding universe of p53 targets. Nat Rev Cancer (2009) 3.49
p53 dynamics control cell fate. Science (2012) 3.30
The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci U S A (2002) 3.11
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol (2002) 3.08
CDK8 is a stimulus-specific positive coregulator of p53 target genes. Mol Cell (2007) 2.88
The ribonucleotide reductase inhibitor Sml1 is a new target of the Mec1/Rad53 kinase cascade during growth and in response to DNA damage. EMBO J (2001) 2.80
Characterization of genome-wide p53-binding sites upon stress response. Nucleic Acids Res (2008) 2.67
Gene expression patterns associated with p53 status in breast cancer. BMC Cancer (2006) 2.61
Oncogenic ras and p53 cooperate to induce cellular senescence. Mol Cell Biol (2002) 2.61
Functional anthology of intrinsic disorder. 1. Biological processes and functions of proteins with long disordered regions. J Proteome Res (2007) 2.61
p53 isoform delta113p53 is a p53 target gene that antagonizes p53 apoptotic activity via BclxL activation in zebrafish. Genes Dev (2009) 2.57
Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners. BMC Genomics (2008) 2.50
p53 and its mutants in tumor cell migration and invasion. J Cell Biol (2011) 2.49
p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J (2000) 2.38
Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature (2008) 2.32
The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A (2003) 2.29
Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer (2006) 2.16
Stimulus-dependent dynamics of p53 in single cells. Mol Syst Biol (2011) 2.02
H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation. Cell (2013) 2.00
p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Mol Cell Biol (2001) 1.93
Mining alpha-helix-forming molecular recognition features with cross species sequence alignments. Biochemistry (2007) 1.93
An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood (2008) 1.93
Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol (2002) 1.83
WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev (2002) 1.80
NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci U S A (2002) 1.80
Ranked prediction of p53 targets using hidden variable dynamic modeling. Genome Biol (2006) 1.78
MILANO--custom annotation of microarray results using automatic literature searches. BMC Bioinformatics (2005) 1.77
Transcriptional response of lymphoblastoid cells to ionizing radiation. Genome Res (2003) 1.77
Gene-specific repression of the p53 target gene PUMA via intragenic CTCF-Cohesin binding. Genes Dev (2010) 1.76
p53 represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-kappaB subunit with histone deacetylase 1. Mol Cell Biol (2003) 1.75
Methylation-acetylation interplay activates p53 in response to DNA damage. Mol Cell Biol (2007) 1.75
The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci U S A (2003) 1.69
Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci U S A (2003) 1.63
Hsp70 interactions with the p53 tumour suppressor protein. EMBO J (2001) 1.62
A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev (2006) 1.58
Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene (2008) 1.57
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev (2002) 1.57
Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol (2005) 1.54
Lysosomal destabilization in p53-induced apoptosis. Proc Natl Acad Sci U S A (2002) 1.54
Regulation of the p53 transcriptional response by structurally diverse core promoters. Genes Dev (2009) 1.52
A threshold mechanism mediates p53 cell fate decision between growth arrest and apoptosis. Cell Death Differ (2013) 1.50
Functionally distinct polymorphic sequences in the human genome that are targets for p53 transactivation. Proc Natl Acad Sci U S A (2005) 1.49
Another fork in the road--life or death decisions by the tumour suppressor p53. EMBO Rep (2013) 1.43
Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Mol Cell Biol (2002) 1.43
The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res (2005) 1.42
A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint. Genes Dev (2009) 1.42
Unfoldomics of human diseases: linking protein intrinsic disorder with diseases. BMC Genomics (2009) 1.41
Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. Elife (2014) 1.41
Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism. Mol Biol Cell (2007) 1.38
Redefining the p53 response element. Proc Natl Acad Sci U S A (2009) 1.36
Regulation of ultraviolet light-induced gene expression by gene size. Proc Natl Acad Sci U S A (2004) 1.35
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med (2010) 1.35
A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol (2008) 1.34
Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res (2013) 1.33
Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53. Proc Natl Acad Sci U S A (2002) 1.32
Tumor suppressor SMAR1 mediates cyclin D1 repression by recruitment of the SIN3/histone deacetylase 1 complex. Mol Cell Biol (2005) 1.30
Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. Semin Cancer Biol (2008) 1.27
Strategies for manipulating the p53 pathway in the treatment of human cancer. Biochem J (2000) 1.26
Surf the post-translational modification network of p53 regulation. Int J Biol Sci (2012) 1.25
p53 regulates myogenesis by triggering the differentiation activity of pRb. J Cell Biol (2000) 1.25
The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes. Mol Cell Biol (2006) 1.24
The p53 circuit board. Biochim Biophys Acta (2012) 1.24
p53 targets identified by protein expression profiling. Proc Natl Acad Sci U S A (2007) 1.23
Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo. Proc Natl Acad Sci U S A (2001) 1.22
Inhibition of glycolytic enzymes mediated by pharmacologically activated p53: targeting Warburg effect to fight cancer. J Biol Chem (2011) 1.16
p53 responsive elements in human retrotransposons. Oncogene (2009) 1.15
Chromatin immunoprecipitation-based screen to identify functional genomic binding sites for sequence-specific transactivators. Mol Cell Biol (2005) 1.15
Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene (2012) 1.15
Critical roles for the serine 20, but not the serine 15, phosphorylation site and for the polyproline domain in regulating p53 turnover. Biochem J (2001) 1.14
The pro-longevity gene FoxO3 is a direct target of the p53 tumor suppressor. Oncogene (2011) 1.13
Involvement of Rho family GTPases in p19Arf- and p53-mediated proliferation of primary mouse embryonic fibroblasts. Mol Cell Biol (2004) 1.12
Ovol1 regulates meiotic pachytene progression during spermatogenesis by repressing Id2 expression. Development (2005) 1.12
Protein disorder in the human diseasome: unfoldomics of human genetic diseases. BMC Genomics (2009) 1.11
Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis. Mol Cell Biol (2006) 1.09
p53 and NF-κB coregulate proinflammatory gene responses in human macrophages. Cancer Res (2014) 1.09
Expression of androgen receptor is negatively regulated by p53. Neoplasia (2007) 1.08
The p53 tumour suppressor inhibits glucocorticoid-induced proliferation of erythroid progenitors. EMBO Rep (2002) 1.07
Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. PLoS One (2010) 1.04
The direct p53 target gene, FLJ11259/DRAM, is a member of a novel family of transmembrane proteins. Biochim Biophys Acta (2007) 1.04
Human single-nucleotide polymorphisms alter p53 sequence-specific binding at gene regulatory elements. Nucleic Acids Res (2010) 1.03
Apoptosis or growth arrest: Modulation of tumor suppressor p53's specificity by bacterial redox protein azurin. Proc Natl Acad Sci U S A (2004) 1.03
Dose-dependent and independent temporal patterns of gene responses to ionizing radiation in normal and tumor cells and tumor xenografts. Proc Natl Acad Sci U S A (2001) 1.03
Oscillations of the p53-Akt network: implications on cell survival and death. PLoS One (2009) 1.02
p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. Arch Biochem Biophys (2011) 1.02
Negative cross-talk between p53 and the glucocorticoid receptor and its role in neuroblastoma cells. EMBO J (2000) 1.01
Decision Making by p53: Life versus Death. Mol Cell Pharmacol (2010) 1.01
Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. Neuro Oncol (2005) 1.00
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 88.48
Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol (1996) 72.84
Exploring the metabolic and genetic control of gene expression on a genomic scale. Science (1997) 60.15
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A (1999) 35.16
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell (1993) 33.20
p53 mutations in human cancers. Science (1991) 31.96
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol (1997) 27.78
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (1992) 25.54
The transcriptional program in the response of human fibroblasts to serum. Science (1999) 19.19
Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 16.68
p21 is a universal inhibitor of cyclin kinases. Nature (1993) 15.55
Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science (1994) 13.51
Definition of a consensus binding site for p53. Nat Genet (1992) 12.76
Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science (1998) 11.90
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
Wild-type p53 activates transcription in vitro. Nature (1992) 11.39
A model for p53-induced apoptosis. Nature (1997) 11.38
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science (1998) 10.89
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev (1998) 9.03
14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell (1997) 7.20
The p53 pathway. J Pathol (1999) 6.79
Identification of p53 as a sequence-specific DNA-binding protein. Science (1991) 6.60
Presence of a potent transcription activating sequence in the p53 protein. Science (1990) 6.38
Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell (1990) 6.37
Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci U S A (1992) 5.94
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev (1994) 5.68
Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science (1990) 5.47
Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A (1989) 5.40
E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev (1998) 4.60
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet (1997) 4.46
Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06
The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev (1993) 3.99
P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A (1999) 3.78
ATM associates with and phosphorylates p53: mapping the region of interaction. Nat Genet (1998) 3.66
Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A (1994) 3.36
Caveolae and caveolins. Curr Opin Cell Biol (1996) 3.25
Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53. Mol Cell (1999) 2.93
p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med (1998) 2.91
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
p53 domains: identification and characterization of two autonomous DNA-binding regions. Genes Dev (1993) 2.74
Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev (1997) 2.70
Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature (1993) 2.61
A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. Genes Dev (1993) 2.53
Recombinant 47-kilodalton cytosol factor restores NADPH oxidase in chronic granulomatous disease. Science (1989) 2.39
Use of the two-hybrid system to identify the domain of p53 involved in oligomerization. Oncogene (1993) 2.33
Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev (1996) 1.86
Ultraviolet radiation, but not gamma radiation or etoposide-induced DNA damage, results in the phosphorylation of the murine p53 protein at serine-389. Proc Natl Acad Sci U S A (1998) 1.70
p53 domains: structure, oligomerization, and transformation. Mol Cell Biol (1994) 1.68
Annexin XIIIb: a novel epithelial specific annexin is implicated in vesicular traffic to the apical plasma membrane. J Cell Biol (1995) 1.68
Light-directed synthesis of high-density oligonucleotide arrays using semiconductor photoresists. Proc Natl Acad Sci U S A (1996) 1.48
A human gene encoding a putative basic helix-loop-helix phosphoprotein whose mRNA increases rapidly in cycloheximide-treated blood mononuclear cells. DNA Cell Biol (1994) 1.31
MyD genes in negative growth control. Oncogene (1998) 1.20
NRP/B, a novel nuclear matrix protein, associates with p110(RB) and is involved in neuronal differentiation. J Cell Biol (1998) 1.18
Mutational spectra and immunohistochemical analyses of p53 in human cancers. Chest (1992) 1.02
Induction of Rb-associated protein (RbAp46) by Wilms' tumor suppressor WT1 mediates growth inhibition. J Biol Chem (1998) 0.93
Mouse models dissect the role of p53 in cancer and development. Semin Cancer Biol (1998) 0.92
The sequence of the human genome. Science (2001) 101.55
Surfing the p53 network. Nature (2000) 35.36
Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A (1999) 35.16
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell (1992) 16.53
Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell (1979) 14.05
DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science (1988) 13.46
Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science (1990) 12.88
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19
Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet (2011) 10.73
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science (1996) 9.48
Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. Cell (1982) 9.27
ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem (2001) 8.78
Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet (1994) 6.89
Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol (1996) 6.64
Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol (1988) 6.44
Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev (1991) 6.30
Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. Mol Cell Biol (1981) 6.02
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev (1994) 5.68
p53 and E2F-1 cooperate to mediate apoptosis. Proc Natl Acad Sci U S A (1994) 5.49
Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol (1993) 5.31
Identification of human immunodeficiency virus sequences by using in vitro enzymatic amplification and oligomer cleavage detection. J Virol (1987) 5.27
Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J (1998) 4.98
Growth regulation of a cellular tumour antigen, p53, in nontransformed cells. Nature (1984) 4.86
Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol (1989) 4.63
Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulin-secreting cells. Cell (1994) 4.60
Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med (1987) 4.54
Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by oligonucleotide arrays. Cancer Res (2001) 4.50
Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ (1995) 4.50
DNA replication in SV40 infected cells. I. Analysis of replicating SV40 DNA. J Mol Biol (1970) 4.49
c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature (2001) 4.46
Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. Cell Growth Differ (1990) 4.32
Transcriptional silencing of Ty1 elements in the RDN1 locus of yeast. Genes Dev (1997) 4.31
LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity (1998) 4.23
Gain of function mutations in p53. Nat Genet (1993) 4.19
Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06
Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med (1993) 4.04
Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells. Mol Cell Biol (1985) 4.03
p53 alteration is a common event in the spontaneous immortalization of primary BALB/c murine embryo fibroblasts. Genes Dev (1991) 4.01
Increases in platelet and red cell counts, blood viscosity, and arterial pressure during mild surface cooling: factors in mortality from coronary and cerebral thrombosis in winter. Br Med J (Clin Res Ed) (1984) 4.00
Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol (1998) 3.99
The process of infection with bacteriophage phiX174. XXV. Studies with bacteriophage phiX174 mutants blocked in progeny replicative form DNA synthesis. J Mol Biol (1969) 3.87
P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci U S A (1999) 3.78
Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A (2000) 3.74
WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A (1998) 3.73
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell (1984) 3.56
Isolation and characterization of polyoma host range mutants that replicate in nullipotential embryonal carcinoma cells. Proc Natl Acad Sci U S A (1981) 3.55
Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol (2004) 3.52
Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev (1999) 3.41
Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature (1995) 3.39
Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol Cell Biol (1983) 3.39
Galactorrhoea and hyperprolactinaemia associated with protease-inhibitors. Lancet (2000) 3.38
Adenovirus early region 1B 58,000-dalton tumor antigen is physically associated with an early region 4 25,000-dalton protein in productively infected cells. J Virol (1984) 3.38
Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev (1992) 3.37
Functions of the MDM2 oncoprotein. Cell Mol Life Sci (1999) 3.35
The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. Virology (1979) 3.33
DNA-binding proteins specific for cells infected by adenovirus. Nat New Biol (1973) 3.30
Thermolabile DNA binding proteins from cells infected with a temperature-sensitive mutant of adenovrius defective in viral DNA synthesis. J Virol (1975) 3.29
Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci U S A (1992) 3.27
Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol (2000) 3.18
The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes. Mol Cell Biol (1994) 3.16
Computer support for interpreting family histories of breast and ovarian cancer in primary care: comparative study with simulated cases. BMJ (2000) 3.12
The p53MH algorithm and its application in detecting p53-responsive genes. Proc Natl Acad Sci U S A (2002) 3.11
Targeted prevention of unipolar depressive disorder in an at-risk sample of high school adolescents: a randomized trial of a group cognitive intervention. J Am Acad Child Adolesc Psychiatry (1995) 3.08
Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex. J Virol (1986) 3.04
Immunological evidence for the association of p53 with a heat shock protein, hsc70, in p53-plus-ras-transformed cell lines. Mol Cell Biol (1987) 3.01
Conversion of the lac repressor into an allosterically regulated transcriptional activator for mammalian cells. Mol Cell Biol (1990) 3.00
Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res (1994) 2.98
A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit. Infect Control Hosp Epidemiol (1992) 2.98
Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A (1999) 2.89
Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat Genet (1999) 2.81
Childhood incidence of acute lymphoblastic leukaemia and exposure to broadcast radiation in Sydney--a second look. Aust N Z J Public Health (1998) 2.79
mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol (1996) 2.78
Human TAFII31 protein is a transcriptional coactivator of the p53 protein. Proc Natl Acad Sci U S A (1995) 2.76
Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. Virology (1983) 2.69
WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev (2000) 2.67
Consensus development methods: a review of best practice in creating clinical guidelines. J Health Serv Res Policy (1999) 2.66
A monoclonal antibody detecting the adenovirus type 5-E1b-58Kd tumor antigen: characterization of the E1b-58Kd tumor antigen in adenovirus-infected and -transformed cells. Virology (1982) 2.65
Identification and mapping of Epstein-Barr virus early antigens and demonstration of a viral gene activator that functions in trans. J Virol (1986) 2.64
The 65,000-Mr DNA-binding and virion trans-inducing proteins of herpes simplex virus type 1. J Virol (1987) 2.63
Lens injury stimulates axon regeneration in the mature rat optic nerve. J Neurosci (2000) 2.56
A comparison of the biological activities of wild-type and mutant p53. FASEB J (1993) 2.49
Characterization of monoclonal antibodies and polyclonal immune sera directed against human cytomegalovirus virion proteins. Virology (1984) 2.48
The p53 functional circuit. J Cell Sci (2001) 2.46
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J (1992) 2.45
Mechanism by which fiber antigen inhibits multiplication of type 5 adenovirus. J Virol (1967) 2.44
Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like signal sequence. EMBO J (1997) 2.44
Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med (1995) 2.44
Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol (1994) 2.44
Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med (2003) 2.44
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene (1999) 2.43
Identification and characterization of an immunologically conserved adenovirus early region 11,000 Mr protein and its association with the nuclear matrix. J Mol Biol (1982) 2.36
Detection of hepatitis B virus sequences in serum by using in vitro enzymatic amplification. J Virol Methods (1988) 2.36
Induced alpha helix in the VP16 activation domain upon binding to a human TAF. Science (1997) 2.35
TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J Cell Sci (1997) 2.35
A chimeric mammalian transactivator based on the lac repressor that is regulated by temperature and isopropyl beta-D-thiogalactopyranoside. Proc Natl Acad Sci U S A (1991) 2.35